+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hyperphosphatemia Drugs Market 2019-2027

  • ID: 4791835
  • Report
  • Region: Global
  • 123 pages
  • Triton Market Research
1 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
Market Outlook

After a detailed analysis, This research has concluded that the global hyperphosphatemia drugs market is expected to display an upward trend and is estimated to grow at a CAGR of 16.61% in terms of revenue over the forecast period of 2019 to 2027.

Hyperphosphatemia normally affects individuals in the late stages of kidney disease. Diabetes and hypertension are major causes of renal dysfunction. A rise in the prevalence of these conditions increases the number of people with CKD that are on dialysis. Phosphate binders are used to treat hyperphosphatemia, but the drugs have some adverse effects. This leads to the increased need for effective treatment options, compelling vendors to extensively invest in the R&D of new drugs. The prevalence of chronic kidney diseases in the elderly population is very high, with more than 35% of patients over 70 years of age suffering from stage 3 chronic kidney disease. This has increased the use of phosphate binding drugs in the market. Phosphorus is essential for normal physiological functions such as bone construction, nerve function, and muscle contraction. Most of the phosphorus is stored in the bones and different tissues of the body.

The rapidly growing chronic disorders, rising public awareness and the growth in the elderly population are the key driving factors of the hyperphosphatemia drugs market. Factors such as the strict FDA regulations and the side-effects caused due to the consumption of hyperphosphatemia drugs are obstructing the growth of this industry. The growing aging populace is a key opportunity that can be leveraged by this market in order to supplement further growth. However, the option of choosing alternative dialysis techniques as well as non-adherence to treatment regimes and limited access to drugs are the challenges being faced by the hyperphosphatemia drugs market at this moment.

Regional Outlook

The main regions included in the hyperphosphatemia drugs market are North America, Europe, Latin America, APAC and the Middle East and Africa.

North America is the clear leader in the global hyperphosphatemia drugs market in terms of revenue. The hyperphosphatemia drugs market in North America is driven by the increasing rate of a number of chronic kidney disorders and increasing prevalence of diabetes & osteoporosis across the region. Asia-Pacific is the fastest-growing region in the hyperphosphatemia drugs market. China is expected to be the largest healthcare drugs and equipment market in Asia-Pacific region both by revenue and size. The rapidly expanding healthcare infrastructure throughout the country, driven solid growth efforts being undertaken by the country’s central government is projected to fuel demand for hyperphosphatemia drugs across China.

Competitive Outlook

Sanofi, Pfizer, Inc., Zeria Pharmaceutical, Bio-Tech Pharmacal, Roche Diagnostics Corporation, Ultragenyx Pharmaceutical, Inc., Fresenius Medical Care, Shire, Keryx Biopharmaceuticals, Inc., Royal DSM N.V., Fermenta Biotech, Ltd., Cipla, Bruno Farmaceutici S.p.A., Johnson and Johnson, Sun Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals are the companies leading the hyperphosphatemia drugs market.

Bruno Farmaceutici S.p.A. is the manufacturer and marketer of the pharmaceutical products. The company is dedicated to improving health by deploying the production and supply of the drugs and provides quality, efficacy and safety. The company’s product, Diosmix, is a disposable device which comes in a sachet and is in the form of a powder for extemporaneous oral suspension. It is for the treatment of chronic diarrheas and gastrointestinal diseases’ painful symptoms. Orexigen Therapeutics Ireland has announced an agreement with Bruno Farmaceutici S.p.A. for the commercialization and distribution of Mysimba.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
1. Global Hyperphosphatemia Drugs Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Porter’s Five Force Model
2.2.1. Threat of New Entrants
2.2.2. Bargaining Power of Buyers
2.2.3. Bargaining Power of Suppliers
2.2.4. Threat of Substitute Product
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Key Buying Outlook
2.5. Key Insights
2.6. Key Market Trends
2.7. Guidelines Related to the Phosphate Binders
2.8. Market Drivers
2.8.1. Chronic Disorders are Increasing Rapidly
2.8.2. Increase in Public Cognizance
2.8.3. Increase in Geriatric Population
2.9. Market Restraints
2.9.1. Side-Effects Related to the Usage of Hyperphosphatemia Drugs
2.9.2. Strict Food and Drug Administration (Fda) Regulations
2.10. Market Opportunities
2.10.1. Rise in the Aging Population
2.11. Market Challenges
2.11.1. Alternative Dialysis Techniques
2.11.2. Accessibility of Drugs is Limited
2.11.3. Non-Adherence to Treatment Regimes

3. Hyperphosphatemia Drugs Market Outlook - By Dosages
3.1. Solid
3.1.1. Tablet
3.1.2. Powder
3.2. Liquid
3.2.1. Solution

4. Hyperphosphatemia Drugs Market Outlook - By Formulation
4.1.1. Calcium-Based Phosphate Binders
4.1.2. Aluminum-Based Phosphate Binders
4.1.3. Magnesium-Based Phosphate Binders
4.1.4. Iron-Based Phosphate Binders
4.1.5. Other Phosphate Binders

5. Hyperphosphatemia Drugs Industry – Regional Outlook
5.1. North America
5.1.1. Market By Formulation
5.1.2. Country Analysis
5.1.2.1. United States
5.1.2.2. Canada
5.2. Europe
5.2.1. Market By Formulation
5.2.2. Country Analysis
5.2.2.1. United Kingdom
5.2.2.2. France
5.2.2.3. Germany
5.2.2.4. Spain
5.2.2.5. Italy
5.2.2.6. Russia
5.2.2.7. Rest of Europe (Roe)
5.3. Asia Pacific
5.3.1. Market By Formulation
5.3.2. Country Analysis
5.3.2.1. India
5.3.2.2. China
5.3.2.3. Japan
5.3.2.4. Australia
5.3.2.5. Rest of Apac
5.4. Latin America
5.4.1. Market By Formulation
5.4.2. Country Analysis
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East and Africa (Mea)
5.5.1. Market By Formulation
5.5.2. Country Analysis
5.5.2.1. Saudi Arabia
5.5.2.2. Turkey
5.5.2.3. United Arab Emirates
5.5.2.4. South Africa
5.5.2.5. Rest of Middle East and Africa

6. Competitive Landscape
6.1. Johnson and Johnson
6.2. Zeria Pharmaceutical
6.3. Amag Pharmaceuticals
6.4. Sanofi
6.5. Bruno Farmaceutici S.P.A.
6.6. Roche Diagnostics Corporation
6.7. Royal Dsm N.V.
6.8. Shire
6.9. Cipla
6.10. Ultragenyx Pharmaceutical, Inc.
6.11. Fermenta Biotech, Ltd.
6.12. Biotech Pharmacal
6.13. Sun Pharmaceutical Industries, Ltd.
6.14. Keryx Biopharmaceuticals, Inc.
6.15. Fresenius Medical Care
6.16. Pfizer, Inc.

7. Methodology & Scope
7.1. Research Scope
7.2. Sources of Data
7.3. Research Methodology

List of Tables
Table 1 Global Hyperphosphatemia Drugs Market By Region 2019-2027 ($ Million)
Table 2 Phosphorous Levels in Select Foods
Table 3 Global Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 4 Diagnosis and Clinical Indicators of Chronic Kidney Disease
Table 5 North America Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 6 North America Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)
Table 7 Europe Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 8 Europe Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)
Table 9 Asia-Pacific Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 10 Asia-Pacific Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)
Table 11 Per Capita Consumption of Dairy Products in Australia
Table 12 Latin America Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 13 Latin America Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)
Table 14 Middle East and Africa Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 15 Middle East and Africa Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)

List of Figures
Figure 1 Porter’s Five Force Model of Hyperphosphatemia Market
Figure 2 Iron-Based Hyperphosphatemia Drug Approval Status 2014-2017
Figure 3 Global Population Aged 80 and Above 1950-2050 (Million)
Figure 4 Rate of Adherence to Phosphate Binders
Figure 5 Global Hyperphosphatemia Drugs Market in Calcium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 6 Global Hyperphosphatemia Drugs Market in Aluminum-Based Phosphate Binders 2019-2027 ($ Million)
Figure 7 Global Hyperphosphatemia Drugs Market in Magnesium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 8 Global Hyperphosphatemia Drugs Market in Iron-Based Phosphate Binders 2019-2027 ($ Million)
Figure 9 Global Hyperphosphatemia Drugs Market in Other Phosphate Binders 2019-2027 ($ Million)
Figure 10 Global Hyperphosphatemia Drugs Market Share By Region 2018 & 2027 (%)
Figure 11 North America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 12 United States Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 13 Canada Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 14 Europe Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 15 United Kingdom Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 16 France Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 17 Germany Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 18 Spain Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 19 Italy Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 20 Russia Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 21 Rest of Europe Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 22 Asia-Pacific Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 23 Agewise Distribution of Elderly Population in India
Figure 24 India Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 25 China Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 26 Japan Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 27 Number of Fractures Due to Osteoporosis and Osteopenia
Figure 28 South Korea Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 29 Asean Countrieshyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 30 Australia & New Zealand Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 31 Roapac Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 32 Latin America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 33 Brazil Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 34 Mexico Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 35 Rest of Latin America Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 36 Middle East and Africa Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 37 Saudi Arabia Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 38 Turkey Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 39 United Arab Emirates Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 40 South Africa Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 41 Rest of Middle East & Africa Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Johnson and Johnson
  • Zeria Pharmaceutical
  • Amag Pharmaceuticals
  • Sanofi
  • Bruno Farmaceutici S.P.A.
  • Roche Diagnostics Corporation
  • Royal Dsm N.V.
  • Shire
  • Cipla
  • Ultragenyx Pharmaceutical, Inc.
  • Fermenta Biotech, Ltd.
  • Biotech Pharmacal
  • Sun Pharmaceutical Industries, Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Fresenius Medical Care
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll